Name: MANNKIND CORP (MNKD) Stock
Brand: MANNKIND CORP
Rating: 7.5 (3 reviews)

MNKD Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Chartmill

MannKind Corp (NASDAQ:MNKD) Reports Q3 2025 Earnings Beat, Shares Rise

3 days ago - By: MannKind

MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

3 days ago - By: Stocktwits

MannKind Stock Nears Breakout As FDA Reviews First New Insulin For Kids In A Century

4 days ago - By: Stocktwits - Mentions: URTY PBE

MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters

4 days ago - By: Zacks Investment Research

MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say

4 days ago - By: Zacks Investment Research - Mentions: OVID

MannKind (MNKD) Tops Q3 Earnings and Revenue Estimates

4 days ago - By: MannKind

MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

4 days ago - By: MannKind

MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

4 days ago - By: Benzinga - Mentions: TECH INSE GEF SKYT ...

Earnings Scheduled For November 5, 2025

10 days ago - By: Zacks Investment Research - Mentions: PTGX

Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy?

11 days ago - By: MannKind

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

11 days ago - By: MannKind

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

a month ago - By: MannKind

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

a month ago - By: MannKind

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

a month ago - By: MannKind

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

a month ago - By: MannKind

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

a month ago - By: MannKind

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

a month ago - By: MannKind

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

2 months ago - By: Zacks Investment Research - Mentions: DNLI

Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?

2 months ago - By: Benzinga - Mentions: INSM CNC MOH UNH ...

10 Health Care Stocks Whale Activity In Today's Session

2 months ago - By: Stocktwits - Mentions: UTHR

MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results

2 months ago - By: Yahoo Finance

MannKind Corporation (MNKD) Seeks FDA Pediatric Approval for Afrezza

2 months ago - By: Brodsky & Smith LLC - Mentions: SCPH VTLE IMXI HBI ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: scPharmaceuticals Inc. (Nasdaq – SCPH), Vital Energy, Inc. (NYSE – VTLE), International Money Express, Inc. (Nasdaq - IMXI), HanesBrands Financial Corp. (NYSE - HBI)

2 months ago - By: MannKind

MannKind to Present at Upcoming Investor Conferences

2 months ago - By: MannKind

MannKind to Present at Upcoming Investor Conferences

2 months ago - By: Stocktwits - Mentions: UTHR

MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together

2 months ago - By: MannKind

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

2 months ago - By: MannKind

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

2 months ago - By: Zacks Investment Research - Mentions: CVGI INBK

New Strong Sell Stocks for August 27th

3 months ago - By: Stocktwits - Mentions: SCPH

MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish

3 months ago - By: Stocktwits - Mentions: SCPH

MannKind Corporation to Acquire scPharmaceuticals: More Details Inside

3 months ago - By: MannKind - Mentions: SCPH

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

3 months ago - By: MannKind

MANNKIND CORP (MNKD) Stock News

MNKD Latest News, Press Relases and Analysis